CAMP4 Therapeutics Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
CAMP4 Therapeutics Corporation (CAMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $45.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-05
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $43.00K, a 80.63% decline year-over-year.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $2.00K.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $0.00.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $0.00.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $45.00K, a 99.32% decline from fiscal 2024.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $6.60M, a 3200.00% increase from fiscal 2023.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $200.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $45.00K derived: sum of 2 quarters · filed 2026-03-05 | $45.00K derived: sum of 3 quarters · filed 2026-03-05 | $45.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.00K derived: sum of 2 quarters · filed 2025-11-06 | $2.00K 10-Q · filed 2025-11-06 | $224.00K derived: sum of 4 quarters · filed 2026-03-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $222.00K derived: sum of 3 quarters · filed 2026-03-05 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $222.00K derived: sum of 2 quarters · filed 2026-03-05 | |||
| 2024-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.60M 10-K · filed 2026-03-05 | $6.58M 10-K · filed 2025-03-27 | ||
| 2024-09-30 | $6.38M 10-Q · filed 2024-11-21 | ||||
| 2023-12-31 | $200.00K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |